NCT06619600View on ClinicalTrials.gov

Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 30, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
ST-segment Elevation Myocardial Infarction (STEMI)Diabetes MellitusHeart FailureMyocardial Fibrosis
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10 mg qd

DRUG

Placebo

Matched placebo qd

Trial Locations (2)

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08036

Hospital Clinic of Barcelona, Barcelona

All Listed Sponsors
lead

Hospital Clinic of Barcelona

OTHER

NCT06619600 - Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction | Biotech Hunter | Biotech Hunter